据媒体报道，近日奈雪的茶河南驻马店一家门店张贴通知称"能喝奶茶就不要喝水"，此事引发争议。4月29日，话题#奈雪的茶门店通知能喝奶茶就不要喝水 #登上微博热搜第二。 南都湾财社记者注意到，涉事门店为奈雪的茶（玖隆茂店），该门店于社交平台账号发布帖子称"能喝奶茶就不要喝水，节约用水从我做起"，并附上"一本 正经的胡说八道""抽象"的话题标签。此外，图片显示，门店张贴的通知显示，"由于天气炎热，用水量剧增。很多淡水资源已经亮起了红灯。希望各位市民 节约用水，能喝奶茶就不要喝水。把水留给不能喝奶茶的孩子，将爱心传播下去"。 4月29日，南都湾财社记者搜索发现，该门店账号已清空账号内容。涉事门店工作人员告诉南都湾财社记者，这是模仿网络搞笑段子，门店当天拍完照后便 撤掉了，没有继续摆放该通知。 同日，奈雪的茶相关负责人回应南都湾财社记者称，经调查，此举为个别加盟门店行为，总部发现后已立即叫停，并责令撤销相关内容，公司将进一步加强 门店管理，杜绝此类事情再发生。 奈雪的茶（02150.HK）起源于深圳，创立于2015年，2021年其在港交所挂牌上市。2024年财报显示，2024年，奈雪的茶营收同比下滑4.71%至49.2 ...

商家配发的《重要通知》图片上，白纸黑字印着：由于天气炎热，用水量剧增，很多淡水资源已经亮起 了红灯，希望各位市民节约用水。能喝奶茶就不要喝水，把水留给不能喝的孩子，将爱心传播下去。节 约用水，从我做起。 4月29日，#奈雪的茶门店通知能喝奶茶就不要喝水#冲上热搜。不少网友评论表示："有些玩笑开不 得""喝出毛病第一个找他"。 还有网友评论表示："能喝水就不要喝奈雪的茶"。 网友："喝出毛病第一个找他"。 近日，有网友反映，奈雪的茶(玖隆茂店)小红书在门店摆出重要通知，宣称"能喝奶茶就不要喝水。"这 是对消费者的一种误导。 4月28日晚上，媒体从奈雪的茶(玖隆茂店)小红书账号上看到了这条发布于4月25日的帖文。帖文的标题 是《发布一条重要通知》，配文为："能喝奶茶就不要喝水，节约用水从我做起"！帖文后还附带了话 题"一本正经的胡说八道""一般人我不告诉他"等。 4月29日上午，奈雪的茶(玖隆茂店)一名工作人员向合新闻记者证实，前几天门店的确摆放出了这样一 份《重要通知》，是店长打印出来摆放在门店的，但自己不清楚为何店长要摆放这样的通知。工作人员 称，奈雪的茶(玖隆茂店)是一家加盟店，这份《重要通知》只在门店柜台 ...

智通财经APP讯，满贯集团(03390)发布公告，于2025年4月29日，本公司与认购人Jacobson Group Treasury Limited，订立认购协议，本公司已有条件同意配发及发行，及认购人已有条件同意认购9400万 股认购股份，认购价为每股认购股份0.5港元。 根据认购事项将予配发及发行的9400万股认购股份总数，占于本公告日期本公司已发行股本的11.75%; 及透过发行认购股份扩大的本公司已发行股本约10.51%(假设自本公告日期起直至完成本公司已发行股 本并无变动，因认购事项产生者除外)。认购股份须受自完成日期起计6个月的禁售期所规限。 认购事项所得款项总额合共将为4700万港元，而认购事项所得款项净额(经扣除开支后)估计将合共约为 4670万港元。认购事项的全部所得款项净额拟用作投资于其核心业务以促进增长及扩展，改善其供应链 及物流业务以及一般营运资金。 董事会已通过一项批准认购事项的决议案。本公司认为，认购事项可增强本集团的财务状况，并为本集 团提供营运资金以应对任何未来发展及责任。本公司了解到，认购人拟长期持有于本公司的权益。雅各 臣科研制药集团为领先制药公司，凭藉在开发、生产及分销 ...

Core Insights - The instant delivery industry in China is experiencing rapid growth, with order volume reaching 42 billion in 2023 and expected to exceed 48 billion in 2024, moving towards a trillion-level market [1] - The growth is driven by a combination of diversified traffic channels, integration with instant retail, expansion of food supply, digitalization in lower-tier markets, and the application of new technologies like AI and drones [1][2] - SF Express is leading the industry by connecting upstream traffic and demand through a unique independent third-party position, enhancing service models, and advancing AI and unmanned delivery technologies [1][4] Industry Trends - The instant delivery sector is projected to continue its rapid expansion, with significant contributions from AI and unmanned technologies that enhance operational efficiency and service quality [2][4] - The integration of green and sustainable practices is becoming a core part of the operational framework, with SF Express adopting electric vehicles and AI-driven logistics systems to reduce carbon emissions [2][5] Company Initiatives - SF Express has successfully implemented unmanned vehicle delivery across multiple regions, achieving over a thousand active routes monthly, significantly improving delivery efficiency [4] - The company has reported a 98% usage of green transportation methods in its delivery operations, saving 2.42 million tons of carbon emissions [5] - SF Express is committed to social responsibility, with a focus on creating a supportive ecosystem for its delivery personnel, including safety training and welfare initiatives [6][7] Future Outlook - SF Express aims to maintain its position as an independent third-party instant delivery service, leveraging its full-service network and exploring new models empowered by AI and unmanned technologies [8] - The company is focused on building a collaborative ecosystem that benefits consumers, merchants, and society, contributing to high-quality development in the instant delivery industry [8]

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 0.8% to 743.38 points, with a trading volume of 12.742 billion yuan [1] - The index has experienced a decline of 1.19% over the past month, but has increased by 28.61% over the last three months and by 26.81% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect framework [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (11.68%), WuXi Biologics (10.35%), BeiGene (10.3%), CanSino Biologics (9.55%), CSPC Pharmaceutical Group (7.56%), China Biologic Products (6.68%), Hansoh Pharmaceutical (4.26%), Zai Lab (4.07%), 3SBio (3.58%), and WuXi AppTec (3.58%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a sector breakdown showing that biopharmaceuticals account for 48.63%, chemical drugs for 29.62%, pharmaceutical and biotechnology services for 20.56%, and medical commerce and services for 1.19% [2] - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December each year, ensuring that the weight factors are updated accordingly [2]

Core Viewpoint - Kangzheng Pharmaceutical is planning to spin off its subsidiary, Demai Pharmaceutical, which focuses on skin health, for independent listing on the Hong Kong Stock Exchange. This move raises questions about whether it is a strategic decision or an attempt to offload a loss-making entity [1][4]. Group 1: Spin-off Details - The spin-off will involve a distribution of 90.8% of Demai's shares to existing shareholders, with no new stock issuance for financing. This allows shareholders to directly hold shares of Demai and benefit from independent valuation premiums [1][2]. - Demai Pharmaceutical has shown revenue growth from 384 million yuan in 2022 to 618 million yuan in 2024, but its losses have also increased from 55.17 million yuan to 106 million yuan during the same period [2][3]. Group 2: Financial Performance - Demai's gross margin for prescription drugs is projected to decline from 76.6% in 2023 to 61.7% in 2024, contributing to an overall gross margin drop from 76.9% to 63.5% [2][3]. - The company's sales expense ratio has risen from 57.7% to 62.9%, with sales expenses reaching 388 million yuan in 2024, nearly matching its gross profit [2][3]. Group 3: Strategic Context - Kangzheng Pharmaceutical is facing significant performance pressure, with a revenue decline of 6.8% to 7.469 billion yuan and a net profit drop of 32.3% to 1.613 billion yuan in 2024. The decline is attributed to the impact of national procurement policies on key products [4][5]. - The spin-off aims to achieve three objectives: shedding the loss-making skin business, allowing Demai to raise capital independently, and enhancing the overall market valuation of the group by focusing on higher-margin areas [4][5]. Group 4: Market Landscape - The skin health market is projected to grow significantly, with an estimated market size of 254.9 billion yuan by 2035 and a compound annual growth rate exceeding 15% [4]. - However, Demai faces intense competition from stronger players in the skin health sector, and its reliance on generic products and high sales expenses raises concerns about sustainability [5].

Core Viewpoint - Li Ning Company has made significant strides in sustainable development, integrating ESG principles into its corporate strategy and achieving notable recognition in the industry for its efforts in environmental, social, and governance practices [1][20]. Group 1: ESG Report and Recognition - In April 2025, Li Ning Company released its 2024 ESG report, outlining its sustainable development strategies and practices across various domains, including environmental products, green operations, and social responsibility [1]. - The company achieved a MSCI ESG rating upgrade to BBB and was ranked 15th in the "Kantar BrandZ Sustainable Brands Top 50," leading its industry peers [1]. Group 2: Environmental Product Innovations - In 2024, Li Ning launched China's first fully biodegradable professional sports shoes and established a product standard for biodegradable performance in footwear [3]. - The company reported a carbon reduction of over 30,000 tons through the application of eco-friendly technologies in its shoe production [3]. Group 3: Sustainable Practices in Apparel - Li Ning utilized 2,024 tons of recycled polyester yarn in 2024, resulting in a carbon reduction of 2,283 tons, and repurposed over 150 million plastic bottles in its sportswear [5]. - Approximately 80% of shoe boxes were FSC certified, leading to significant savings in ink, water, and electricity, while reducing carbon emissions by about 118 tons [5]. Group 4: Green Operations and Energy Efficiency - The company implemented smart technology upgrades in its operations, achieving energy savings of over 430,000 kWh in its Shenzhen center alone [6][8]. - Li Ning's headquarters and stores have adopted renewable energy solutions, with self-generated electricity accounting for about 25% of total consumption in its Beijing center [6]. Group 5: Responsible Supply Chain Management - Li Ning completed social responsibility audits for 140 suppliers and environmental audits for 60 suppliers, achieving a 100% pass rate for "excellent" or "good" ratings [9]. - The company established a chemical management framework to ensure zero harmful chemical emissions across its supply chain [9][10]. Group 6: Talent Development and Employer Branding - Li Ning has enhanced its talent development system, focusing on creating a fair and diverse workplace, and received recognition in multiple employer branding awards in 2024 [11][15]. - The company promotes employee well-being through various initiatives, including sports clubs and community events, fostering a strong corporate culture [11]. Group 7: Social Responsibility and Community Engagement - In 2024, Li Ning launched the "2024 Bring Love Home" initiative, donating 2 million yuan worth of supplies to regions in need [16]. - The company supports youth sports development through partnerships and events, such as the "TOP24 Basketball Elite Competition," nurturing new talent in the industry [18].

转自：新华财经 新华财经北京4月29日电（胡晨曦、丁晶）4月29日，泡泡玛特股价收于197.50港元／股，今年以来的涨 幅已经超过120%。2024年，泡泡玛特股价上涨349.60%，同期的香港恒生指数上涨17.67%。 去年以来，以漫画、动漫、游戏等IP为原型的二次元周边商品，通过赋予商品"陪伴"和"精神消费"等情 绪价值，正在成为年轻人的消费新宠。数据显示，相关企业数量已超667万家，96.7%的企业为近5年内 新成立。 除了泡泡玛特旗下的"前方高能"系列盲盒产品引发抢购风潮，来自中国的卡牌在eBay上的交易额也屡创 新高，"中国乐高"布鲁可的海外社交平台粉丝已突破百万。 受旗下IP LABUBU在全球发售受到热捧的带动，泡泡玛特App于4月25日登顶美国App Store购物榜，并 一跃成为App Store免费总榜的第四名。 不仅如此，受访卡游发行商表示，国内二手卡牌"玩家们"已经不满足于国内市场，正在着手开拓更有想 象力的海外市场。 彭博近日汇总的40名分析师中，有38位分析师对泡泡玛特给予"买进"评级，2位分析师给予"持有"评 级。 产品的炙手可热引发了资本市场的青睐。据新华财经统计，与2024年 ...

Core Viewpoint - The company has entered into a collaboration and licensing agreement with Sandoz AG for the development, production, and commercialization of its investigational product HLX13 in specified regions [1] Group 1: Agreement Details - The agreement grants Sandoz AG rights to develop, produce, and commercialize HLX13 in the United States, 42 European countries, Japan, Australia, and Canada [1] - Sandoz AG will pay up to $191 million to the company, which includes an upfront payment of $31 million and milestone payments related to development [1]

Core Points - The China-Hong Kong-US Technology Index has shown a decline of 3.69% over the past month, an increase of 1.09% over the past three months, and a year-to-date increase of 3.43% [1] - The index is composed of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, calculated using an equal-weighted method to reflect the overall performance of these companies [1] - The index's top ten holdings include companies such as SMIC (3.33%), BYD (3.15%), Xiaomi (3.1%), and Alibaba (2.59%) [1] Market Composition - The index's holdings are distributed across various exchanges, with 40.48% on the Nasdaq Global Select Market, 35.64% on the Hong Kong Stock Exchange, and 22.40% on the New York Stock Exchange [2] - In terms of industry composition, Information Technology accounts for 39.01%, Consumer Discretionary for 20.52%, Healthcare for 15.01%, and Communication Services for 13.99% [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]